HIV entry inhibitors

HIV entry inhibitors

A new class of antiretroviral drugs that target the process of entry of HIV into the cell. They include HIV fusion inhibitors and HIV co-receptor antagonists. Enfuvirtide (Fuzeon) was the first entry inhibitor to be developed.
References in periodicals archive ?
In order to efficiently block intracellular fusion events, the next generation of HIV entry inhibitors must be able to permeate the cell membrane," he added.
All the other products mentioned are called HIV entry inhibitors and block HIV infection.
With a far greater understanding of the HIV cell entry process, we can now envisage HIV entry inhibitors as whole new classes of drugs for the future.
HIV entry inhibitors in early development DRUG NAME CURRENTLY GIVEN COMPANY AMD-070 By mouth Anormed AMD-887 By mouth Anormed PRO-140 By injection or infusion * Progenics BMS-488043 By mouth Bristol-Myers Squibb UK 427,857 By mouth Pfizer SP-01A By mouth Samaritan Pharmaceuticals SCH-D By mouth Schering Plough TNX-355 By infusion Tanox GSK(GW)-873140 By mouth GlaxoSmithKline PRO-542 By injection or infusion * Progenics * infusion is when medication is given directly into a vein over a period of time.
In addition, newer agents with novel mechanisms of action, such as HIV entry inhibitors (which inhibit the three steps of HIV entry: CD4 attachment, chemokine co-receptor binding and membrane fusion) and HIV integrase inhibitors, are also under investigation.
Among the new classes of drugs under study are HJV integrase inhibitors, which block the enzyme that HIV uses to incorporate its genetic material into human DNA, and HIV entry inhibitors, which prevent the virus from entering the cell.
Among the new classes of drugs under study are HIV integrase inhibitors, which block the enzyme that HIV uses to incorporate its genetic material into human DNA, and HIV entry inhibitors, which prevent the virus from entering the cell.
Human Immunodeficiency Virus HIV Protease Inhibitors HIV Non-nucleoside Reverse Transcriptase Inhibitors HIV Nucleoside Reverse Transcriptase Inhibitors HIV Entry Inhibitors HIV Integrase Inhibitors Hepatitis C Virus Protease Inhibitors HCV Polymerase Nucleoside Inhibitors Other HCV Inhibitors Respiratory Syncytial Virus Inhibitors Influenza, Hepatitis B, and Cytomegalovirus Inhibitors
Just as the development of HIV entry inhibitors (see page 6 of this issue) grew from discoveries of the mechanism of viral infection in CD4 T cells, so tot) will other discoveries inspire novel therapeutic strategies, perhaps even a cure.
Our HCV entry program leverages our expertise in the discovery and development of HIV entry inhibitors such as PRO 140, which is currently in phase 2 clinical trials.
In the area of virology, Progenics is developing the HIV entry inhibitor PRO 140, a humanized monoclonal antibody targeting the entry co-receptor CCR5, which is in phase 2 clinical testing.
The Company believes that viral-resistance testing may identify patients who will derive the greatest benefit from therapy with HIV entry inhibitors.